HTO Nevada Inc. Recalls Lidocaine Cream Due to Stability Data
Summary
HTO Nevada Inc. is recalling its MAXIMUM, ZONE 1, 4% Lidocaine Cream (NDC 80069-014) nationwide due to stability data not supporting the expiry date. This is a Class II recall, indicating that use of or exposure to the product may cause temporary or medically reversible adverse health consequences.
What changed
HTO Nevada Inc., doing business as Kirkman, is initiating a Class II recall for its MAXIMUM, ZONE 1, 4% Lidocaine Cream (NDC 80069-014) distributed nationwide. The reason for the recall is that the stability data does not support the product's stated expiry date, raising concerns about product efficacy and safety over time.
This recall requires immediate action from distributors and potentially consumers who may possess the affected product. While classified as Class II, which suggests less severe health risks than Class I recalls, the product's integrity is compromised. Companies involved in the distribution chain must ensure the product is removed from inventory and accounted for according to recall procedures. The FDA will monitor the effectiveness of this recall to ensure the product is no longer available to consumers.
What to do next
- Remove affected Lidocaine Cream from inventory
- Comply with FDA recall procedures for Class II recalls
Archived snapshot
Mar 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HTO Nevada Inc. dba Kirkman
Drug Recalls (Class II)
← All Drug Recalls (Class II) Class II D-0386-2026 · 20260311 · Ongoing
Product
MAXIMUM, ZONE 1, 4% Lidocaine Cream, 1/2 oz bottles, Distributed By: Dermal Source, Portland, OR 97232, NDC 80069-014.
Reason for Recall
Stability Data Does Not Support Expiry Date.
Distribution
Nationwide within the U.S
Source: openFDA Enforcement API
Related changes
Get daily alerts for FDA: Drug Recalls Class II
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from FDA.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when FDA: Drug Recalls Class II publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.